| Patient | Diagnosis | Improved ⩾20% | Worsened ⩾30% | Adverse events | Clinical outcome* | CK before/after | MMT before/after | FI before/after |
| 1 | PM | DGA, PGA, HAQ, CK, exm: arthritis | No | No | Improved | 1.8/1.3 | 57/61 | 23/31 |
| 2 | PM | DGA, HAQ, exm: arthritis | exm: skin, dysphagia, myalgia | No | Improved | 1.9/3.9 | 66/73 | 49/54 |
| 3 | PM | HAQ | DGA, CK, exm: myalgia | Abdominal pain, fatigue | Worse | 4/16.8 | 76/77 | 56/58 |
| 4 | PM | No | DGA, CK, exm: arthralgia, myalgia | Abdominal pain, fatigue | Worse | 4.4/8.1 | 65/64 | 34/27 |
| 5 | PM | Dropped out after two infusions | No | Cough | Dropped out | 4.3/– | 54/– | 15/– |
| 6 | DM | DGA, HAQ | CK | Abdominal pain | Unchanged | 1.8/2.7 | 48/56 | 42/42 |
| 7 | DM | Dropped out | No | Toxicodermia | Dropped out | 47/– | 63/– | 40/– |
| 8 | DM | Dropped out | No | Discovered malignancy | Dropped out | 11/– | 68/– | 56/– |
| 9 | DM | Dropped out | CK | Increased general symptoms and muscle fatigue | Dropped out | 88/– | 55/– | – |
| 10 | IBM | DGA, PGA, HAQ | exm: GI, fever | No | Improved | 3.3/2.7 | 61/56 | 32/33 |
| 11 | IBM | No | exm: dysphagia | No | Unchanged | 2.5/2.3 | 49/57 | 25/33 |
| 12 | IBM | DGA | No | Skin, fatigue | Unchanged | 4.6/3.8 | 59/65 | 34/35 |
| 13 | IBM | DGA | No | No | Unchanged | 3.9/3.8 | 57/61 | 33/28 |
*Clinical change according to the IMACS definition,22 .
CK, creatine kinase (men <3.3 μkat/litre, women <2.5 μkat/litre); DGA, doctor’s global assessments of disease activity; exm, extra muscular symptoms; FI, functional index (64 = maximum muscle function); GI, gastrointestinal symptom; HAQ, health assessment questionnaire; MMT, manual muscle test (8 muscle group, scoring 0–10, 80 = maximum strength); PGA, patient’s global assessments of disease activity.